Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677038 · ClinicalTrials.gov registry record · Phase 2
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02677038: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02677038 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02677038, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase II trial studies how well olaparib works in treating patients with stage IV pancreatic cancer. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-11-11 |
| Est. Completion | 2022-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02677038
The ClinicalTrials.gov registry entry for NCT02677038 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olaparib is the first listed.
NCT02677038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02677038 about?
NCT02677038 is a clinical study titled "Olaparib in Treating Patients With Stage IV Pancreatic Cancer". This phase II trial studies how well olaparib works in treating patients with stage IV pancreatic cancer. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02677038?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-11-11. Estimated completion is 2022-07-18.
What interventions are being tested in trial NCT02677038?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT02677038?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.